X-Message-Number: 10515
Date: Fri, 02 Oct 1998 10:25:52 -0700
From: Fred Chamberlain <>
Subject: Reposting of Message #10508 in "Plain Vanilla" Courier (re:

Date:  October 2, 1998
From:  Fred Chamberlain <> and <>
Re:    Reposting of #10508 in "Plain Vanilla" Courier (re: BioTransport)

Posting #10508 contains numerous control code glitches, due to the email
system
used (Eudora Pro 4.0).  For those of you who might have found it unreadable,
the below (hopefully) "cleaned up" version may help.

>From: "B. F. Shelton" <>

(Whose posting no. #10499 asked: "Whatever Happened to BioTransport?")

>I think that was the name of it - being promoted 
>as a joint effort among various cryonics organization
>to provide early response, stabilization and transport, etc.
>Did someone on here mention that talks between Alcor
>and CryoCare did not produce an agreement?  If anyone
>who knows would care to comment, I'd be interested 
>to hear what happened, and what future prospects are.

>B.F.

SIX PHASE DEVELOPMENT PROGRAM

BioTransport, Inc.'s development plan involves a step by step progression, so
far as services are concerned.  There is an active contract between
BioTransport and Alcor for the first three phases at this point, encompassing:
(1) training, (2) logistics support and (3) internet linked consulting
services.  Even these three phases are dependent to a large extent on
capitalization (as discussed further on).

Later phases, still to be negotiated with Alcor, include (4) providing
contract
"team leaders" in field operations to better coordinate volunteer activities,
(5) providing complete teams for field operations (to perform standbys and
transports up to and including circulatory system washout), or providing teams
for cryoprotection and/or cooldown, and (6) turnkey "system contractor"
services where BioTransport assumes end-to-end responsibilities for all
suspensions.  The degree to which all six phases are implemented will
depend on
Alcor's needs for those levels of support, as well as BioTransport's
ability to
demonstrate that it has a reliable capability with adequate quality controls,
satisfying Alcor management.

ORIGINAL CONCEPT AND PRESENT STATUS

BioTransport was originally conceived as a for-profit entity that could take
over Alcor's cryotransport. The thought was that a separate for-profit would
increase the chances of greater suspension team efficiency, faster progress in
technology improvements, and the possibility of better funding through
investment. In addition, there were two possible advantages in separating the
riskiest (from a legal standpoint) part of the suspension procedure from Alcor
itself and in creating an entity outside of Alcor that might have the
potential
to contract with other cryonics organizations someday.

This last advantage became the center of many people's discussions for several
months, and for a while it did seem that a "joint effort" to develop
BioTransport would be possible. However, different groups had different
priorities, so that discussion has been shelved for now.  At this time,
BioTransport is again being developed strictly to take over Alcor's
cryotransport. --We all hope that, once BioTransport is solidly
established, we
can again visit the question of cooperation with other cryonics organizations.

IMMEDIATE PLANS

BioTransport's immediate plans involve adjusting its internal corporate
documentation to support the registration of a DPO (Direct Public Offering),
which would eliminate many of the qualification barriers to purchase of
shares.  The intent is *not* to seek funding from the general public (which
the
name suggests), but rather to be able to open up BioTransport to shareholder
participation among interested cryonicists.  In the beginning, the supporters
might mainly be Alcor Members who want to facilitate the beefing up of rescue
capabilities in their local areas (limited to the Phase I/II/III activity
areas
discussed above).  Later, when we have managed to establish capabilities all
the way to Phase VI (full service), with negotiated service to organizations
other than Alcor, the support base may broaden still further.

Associated with the Phase I/II/III level development activities, in
addition to
preparing for registration of a DPO, we are planning a research project in
which BioTransport and Alcor would cooperate in exploring new technologies to
evaluate and compare existing protocols, as well as monitor the quality of
actual suspensions.  A detailed article will appear in the next issue of
Cryonics Magazine on this subject, and it cannot be reduced to a simple
summary
in a CryoNet posting.  Once that issue of Cryonics Magazine is out, if
questions begin cropping up on CryoNet, I'll try to address them.  The only
purpose of mentioning this work is to indicate that BioTransport will not
solely be a 'service' corporation.

Copies of the research plan for this project (new technologies to
evaluate/compare protocols and monitor suspensions) will be distributed to
Alcor's Scientific and Medical Advisory Boards (now on Alcor's letterhead),
for
comment and recommendations, before we expend any large-scale dollars or
manpower.  Parts of that plan will also appear in BioTransport's prospectus
(DPO registration package), for the benefit of any who want to support this
work by investing in BioTransport vs. donations (tax exempt) to Alcor.

Finally, at the earliest possible time, BioTransport's goal is to facilitate
suspension members' "investing in their own rescue infrastructure".  Many have
stated that they would prefer to invest in a "rescue network", rather than
separately financing their own localized operations.  They would prefer, from
all indications, systematic integration with other groups and a wide
diversification of interests (including research),  to either "going it alone"
or being totally dependent on a distant entity, in the event they need to be
frozen.

SUMMARY

BioTransport, Inc. has an active contract with Alcor and is planning how to
implement this.  The overall activities will be a blend of rescue
infrastructure building and research.

Within a month or so, I'll post a more detailed summary of where BioTransport,
Inc. stands, what it's doing, and what it plans to get done over the next year
or so.  As mentioned above, those who subscribe to Cryonics Magazine will soon
be getting an introduction to what may develop into a central technology for
the joint Alcor/BioTransport research effort. 

Thanks for asking about BioTransport, Inc., B.F.  For the record, in addition
to serving as Alcor's Pres/CEO as shown below, I am holding down (part time)
the job of being BioTransport's "corporate planner."

Boundless Life,

Fred Chamberlain, President/CEO () 
Alcor Life Extension Foundation 
Non-profit cryonic suspension services since 1972. 
7895 E. Acoma Dr., Suite 110, Scottsdale AZ 85260-6916 
Membership Information: (877) GO-ALCOR (462-5267) 
Phone (602) 905-1906 FAX (602) 922-9027
 for general requests
<http://www.alcor.org/>http://www.alcor.org

Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=10515